Skip to main content
. 2022 Dec 28;46(3):561–569. doi: 10.2337/dc22-0908

Figure 4.

Figure 4

Percentages of responders by treatment group. Percentages of participants in the golimumab or placebo groups who had C-peptide levels ≥5% loss from baseline at week 52 (C-peptide), an IDAA1C score of ≤9 at week 52 (partial remission), either or both at week 52. GOL, golimumab group; PBO, placebo group.